The report also shows that between 20 the number of Phase III industry trials initiated in the UK fell by 48. The findings of the report shed light on a serious threat to the long-term future of industry clinical research in the UK along with benefits it brings to patients, the NHS, and the UK economy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |